OptiMARK™ (gadoversetamide injection) is a formulation of a nonionic
gadolinium chelate of diethylenetriamine pentaacetic acid bismethoxyethylamide
(gadoversetamide), for use in magnetic resonance imaging (MRI). OptiMARK™ (gadoversetamide injection)
Injection is to be administered by intravenous injection only.
OptiMARK™ (gadoversetamide injection) Injection is provided as a sterile, nonpyrogenic, clear, colorless
to pale yellow, aqueous solution of gadoversetamide. No preservative is added.
Each mL of OptiMARK™ Injection contains 330.9 mg of gadoversetamide (0.5
millimole), 28.4 mg of calcium versetamide sodium (0.05 millimole), 0.7 mg calcium
chloride dihydrate (0.005 millimole), and water for injection. Sodium hydroxide
and/or hydrochloric acid may have been added for pH adjustment.
OptiMARK™ (gadoversetamide injection) Injection is designated chemically as [8, 11-bis(carboxymethyl)-14-[2-[(2methoxyethyl)amino]-2-oxoethyl]-6-oxo-2-oxa-5,8,11,14-tetraazahexadecan-16-oato(3-)]
gadolinium with a formula weight of 661.77 g/mol and empirical formula of C20H34N5O10Gd.
The structural formula of gadoversetamide in aqueous solution is:
OptiMARK™ (gadoversetamide injection) Injection has a pH of 5.5 to 7.5 and pertinent physiochemical
data are provided below:
Table 1: Physiochemical Data
|Osmolality (mOsmol/kg water)
|| @ 37°C
|| @ 25°C
OptiMARK™ (gadoversetamide injection) Injection has an osmolality of approximately 3.9 times that
of plasma (285 mOsm/kg water) and is hypertonic under conditions of use.
Last reviewed on RxList: 2/11/2011
This monograph has been modified to include the generic and brand name in many instances.